Clinical Trial Update: Tumor Detection Using Iodine-131-Labeled Monoclonal Antibody 8H9 [NA]

View source ↗

Summary

A terminated clinical trial evaluating an iodine-131–labeled monoclonal antibody (8H9) for central nervous system cancers and neuroblastoma has posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Cancer
• Neuroblastoma

Drugs mentioned

• Iodine-131-labeled monoclonal antibody 8H9 (8H9 monoclonal antibody labeled with Iodine-131)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: CNS Cancer, Neuroblastoma | NA | Status: TERMINATED | Results posted: 2017-03-01